Procyon Advisors’s Veracyte VCYT Stock Holding History

Procyon Advisors’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,301	Closed	-$276K	–	603
2025 Q1	$276K	Buy	9,301 +142	+2%	+$5.41K	0.02%	500
2024 Q4	$363K	Sell	9,159 -1,822	-17%	-$69K	0.02%	403
2024 Q3	$374K	Sell	10,981 -4,106	-27%	-$116K	0.03%	398
2024 Q2	$327K	Buy	+15,087	New	+$317K	0.02%	403

Other funds holding VCYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Procyon Advisors's VCYT Position: Q2 2025 in Review

Procyon Advisors sold out of Veracyte (VCYT) in Q2 2025, closing a stake of 9,301 shares — an estimated $276K sold.

Procyon Advisors first reported a position in VCYT in Q2 2024 and held it in 4 quarters. The position peaked at $374K in Q3 2024. 278 funds tracked by Wall St. Rank hold VCYT as of Q2 2025.

Procyon Advisors reported no remaining Veracyte position as of Q2 2025 after selling out during the quarter.
Procyon Advisors sold 9,301 Veracyte shares in Q2 2025, an estimated $276K.
Procyon Advisors first reported a position in Veracyte in Q2 2024 and held it in 4 quarters.
Procyon Advisors's Veracyte position peaked at $374K in Q3 2024.
278 funds tracked by Wall St. Rank held Veracyte as of Q2 2025.

Based on Procyon Advisors's 13F filing for Q2 2025, filed 9 Jul 2025.